Sulforaphane glucosinolate, also known as glucoraphanin, is a naturally occurring compound found primarily in cruciferous vegetables such as broccoli. When consumed, glucoraphanin is converted by the enzyme myrosinase (from either plant or gut microflora) into sulforaphane, a bioactive isothiocyanate. Sulforaphane has been the subject of a significant number of preclinical and clinical studies, particularly regarding its potential benefits for gastrointestinal health, including the small intestine.

Scientific evidence suggests that sulforaphane may support the small intestine by modulating inflammatory responses and enhancing cellular defense mechanisms. Research indicates that sulforaphane activates the Nrf2 pathway, leading to increased expression of phase II detoxification enzymes and antioxidant proteins. These effects can help protect intestinal epithelial cells from oxidative stress and inflammation, which are implicated in several small intestinal disorders.

Some animal and in vitro studies have demonstrated that sulforaphane can reduce intestinal inflammation and permeability, suggesting a protective role for the small intestine. However, clinical trials in humans specifically targeting small intestinal outcomes are limited, and most research has focused on broader gastrointestinal or systemic effects. Nonetheless, the mechanistic data and preliminary animal studies provide a scientific rationale for the use of sulforaphane glucosinolate to support small intestine health, albeit with moderate evidence strength.